Various present, three FDA approved proteasome inhibitors, Bortezomib (PS341,

Various studies have
demonstrated that proteasome inhibition is more toxic in various malignant cell
lines as compared to normal cells. In
vivo studies in cancer cell lines have proven target antagonism of
proteasome inhibitors at high doses level with low toxicity to normal cells (Richardson et al., 2006). At
present, three FDA approved proteasome inhibitors, Bortezomib (PS341, Velcade),
a peptide boronate, Carfilzomib (Kyprolis), a peptide epoxyketone and Ixazomib (MLN9708, Ninlaro®), another
peptide boronate are used routinely in
clinical settings for the treatment of multiple myeloma or
mantle-cell lymphoma in
US and other countries.